查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2031169

全球免疫查核點抑制劑市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Immune Checkpoint Inhibitors Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 160 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球免疫查核點抑制劑市場預計將從2025年的751億美元成長至2034年的3,449.9億美元，2026年至2034年的複合年成長率（CAGR）為18.46%。該市場正經歷快速成長，主要得益於癌症治療中免疫療法的日益普及。免疫查核點抑制劑是一類能夠幫助免疫系統辨識並攻擊癌細胞的藥物，進而改善治療效果。癌症發生率的上升以及對標靶治療日益成長的關注是推動市場擴張的主要因素。

關鍵促進因素包括腫瘤學研究的進展、醫療保健支出的成長以及臨床試驗的擴大。製藥公司正大力投資新型免疫療法和聯合治療的研發。人們對個人化醫療和免疫療法有效性的認知不斷提高，也推動了市場成長。

由於藥物研發和治療方法的持續創新，市場前景依然十分廣闊。生物標記和精準醫療的整合將進一步提高治療效果。隨著醫療基礎設施的不斷完善，新興市場蘊藏著巨大的成長機會。隨著癌症治療的不斷發展，免疫查核點抑制劑市場預計將持續擴張。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業的市場定位、產品系列、策略舉措和財務表現進行了詳細評估。這為了解競爭趨勢和主要參與者所採取的策略提供了寶貴的見解。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球免疫查核點抑制劑市場：按類型分類

  • 市場分析、洞察與預測
  • PD-1
  • PD-L1
  • CTLA-4
  • 其他

第5章 全球免疫查核點抑制劑市場：依應用分類

  • 市場分析、洞察與預測
  • 肺癌
  • 乳癌
  • 膀胱癌
  • 黑色素瘤
  • 子宮頸癌
  • 何傑金氏淋巴瘤
  • 結腸癌
  • 其他

第6章 全球免疫查核點抑制劑市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 全球免疫查核點抑制劑市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Sanofi
    • F. Hoffmann-La Roche Ltd
    • Merck & Co
    • Bristol-Myers Squibb Company
    • Eli Lilly And Company
    • Regeneron Pharmaceuticals Inc
    • AstraZeneca PLC
    • Shanghai Jhunsi Biosciences Ltd
    • Immutep Ltd
    • BeiGene Ltd
    • GlaxoSmithKline PLC
簡介目錄
Product Code: VMR112115300

The global immune checkpoint inhibitors market size is expected to reach USD 344.99 Billion in 2034 from USD 75.10 Billion in 2025, growing at a CAGR of 18.46 during 2026-2034.This market is experiencing rapid growth driven by the increasing adoption of immunotherapy in cancer treatment. Immune checkpoint inhibitors are a class of drugs that help the immune system recognize and attack cancer cells, offering improved treatment outcomes. The rising prevalence of cancer and the growing focus on targeted therapies are significantly contributing to market expansion.

Key drivers include advancements in oncology research, increasing healthcare expenditure, and the expansion of clinical trials. Pharmaceutical companies are investing heavily in the development of new immunotherapies and combination treatments. The growing awareness about personalized medicine and the effectiveness of immunotherapy is also supporting market growth.

Future prospects for this market remain highly promising, with continuous innovation in drug development and treatment approaches. The integration of biomarkers and precision medicine will enhance treatment effectiveness. Emerging markets are expected to offer significant growth opportunities due to improving healthcare infrastructure. As cancer treatment continues to evolve, the immune checkpoint inhibitors market is poised for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Type

  • PD-1
  • PD-L1
  • CTLA-4
  • Others

By Application

  • Lung Cancer
  • Breast Cancer
  • Bladder Cancer
  • Melanoma
  • Cervical Cancer
  • Hodgkin Lymphoma
  • Colorectal Cancer
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

COMPANIES PROFILED

  • Sanofi, F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., AstraZeneca PLC, Shanghai Jhunsi Biosciences Ltd, Immutep Ltd, BeiGene Ltd, GlaxoSmithKline PLC

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET: BY TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type
  • 4.2. PD-1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. PD-L1 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. CTLA-4 Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET: BY APPLICATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Application
  • 5.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Bladder Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Melanoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Cervical Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Hodgkin Lymphoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.8. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Type
    • 7.2.2 By Application
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Type
    • 7.3.2 By Application
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Type
    • 7.4.2 By Application
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Type
    • 7.5.2 By Application
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Type
    • 7.6.2 By Application
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL IMMUNE CHECKPOINT INHIBITORS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 Sanofi
    • 9.2.2 F. Hoffmann-La Roche Ltd
    • 9.2.3 Merck & Co
    • 9.2.4 Bristol-Myers Squibb Company
    • 9.2.5 Eli Lilly And Company
    • 9.2.6 Regeneron Pharmaceuticals Inc
    • 9.2.7 AstraZeneca PLC
    • 9.2.8 Shanghai Jhunsi Biosciences Ltd
    • 9.2.9 Immutep Ltd
    • 9.2.10 BeiGene Ltd
    • 9.2.11 GlaxoSmithKline PLC